Does stopping mineralocorticoid receptor antagonists after an episode of hyperkalaemia reduce recurrent hyperkalaemia or increase death or cardiovascular events?
Stopping MRA therapy after an episode of hyperkalaemia reduces the risk of recurrent hyperkalaemia but is associated with a higher risk of death or cardiovascular events.
Stopping MRA after an episode of hyperkalaemia was associated with reduced risk for recurrent hyperkalaemia, but higher risk of death or cardiovascular events. Recurrent hyperkalaemia was common in either strategy.
Trevisan et al. (Thu,) studied this question.